comparemela.com
Home
Live Updates
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WIT
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WIT
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in...
Related Keywords
Puerto Rico ,
Japan ,
Canada ,
Spain ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Michael Strapazon ,
Jessica Akopyan ,
Amgen Medinfo ,
Kyowa Kirin Co Ltd ,
Amgen ,
American College Of Cardiology ,
Drug Administration ,
World Health Organization ,
Beigene Ltd ,
Exchange Commission ,
European Society Of Cardiology Convention ,
Therapeutics Inc ,
European Union ,
Teneobio Inc ,
Chemocentryx Inc ,
Earlier Treatment With Repatha Resulted ,
Lower Incidence ,
Patients Achieved Guideline Directed ,
Simultaneously Published ,
Hot Line Session ,
European Society ,
Annual Meeting ,
Multimedia News Release ,
Cardiovascular Open Label Extension ,
Dow Jones Industrial Average ,
Best Workplaces ,
Great Place ,
Pharmaceutical Precautions ,
Primary Hyperlipidemia ,
Cardiovascular Outcomes Trial ,
Familial Hypercholesterolemia ,
Pediatric Patients ,
Prescribing Information ,
Five Prime Therapeutics ,
Cardiology Convention ,
American College ,
Cardiovascular Disease Burden ,
Deaths Are Rising Around ,
Cardiovasc Qual ,
Thousand Oaks ,